Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
164 hedge funds and large institutions have $708M invested in Synergy Pharmaceuticals, Inc Common Stock in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 71 increasing their positions, 30 reducing their positions, and 22 closing their positions.
137% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 30
73% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 22
5% more funds holding
Funds holding: 156 → 164 (+8)
1% more capital invested
Capital invested by funds: $700M → $708M (+$8.04M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
54% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $9.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$102M |
| 2 |
State Street
Boston,
Massachusetts
|
+$36.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$30.9M |
| 4 |
O
OrbiMed
New York
|
+$16.9M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.31M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$2.27M |
| 3 |
Citigroup
New York
|
-$2.2M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.88M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.74M |
SGYP Hedge Fund Activity: Q1 2017 in Review
164 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2017, worth a combined $708M — up 1.1% from $700M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SGYP positions and 22 closed out — a net gain of 16 holders — while 71 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $102M. The largest seller was Morgan Stanley, cutting an estimated $2.31M.
- 164 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2017, up from 156 in Q4 2016.
- Funds reported $708M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2017, up 1.1% quarter-over-quarter.
- 38 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2017 and 22 closed out, a net change of +16 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2017 was BlackRock, an estimated $102M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2017 was Morgan Stanley, an estimated $2.31M sold.
Based on aggregated 13F filings for Q1 2017.